Literature DB >> 15446574

[Tumor markers for pancreatic and biliary tract cancer].

Yoriko Takezako1, Takuji Okusaka, Hideki Ueno, Masahumi Ikeda, Chigusa Morizane, Mina Najima.   

Abstract

There are a variety of tumor markers used for diagnosis of pancreatic and biliary tract cancer including carbohydrate antigens such as CA19-9, DUPAN-2, CA50 and Span-1, the carcinoembryonic antigen and pancreatic enzymes such as elastase 1. The tumor marker kinetics in serum help to predict survival in patients receiving surgical and/or non-surgical treatment. Since each of those tumor markers remains at a low sensitivity and specificity in the early stage, none are useful for detecting early cancer. In spite of the development of various diagnostic techniques, pancreas and biliary tract cancer is usually diagnosed at an incurable stage, and the 5-year survival rate is extremely low. Therefore, improvements in survival may well result from screening for early-stage pancreatic and biliary cancer. The development of tumor markers with higher sensitivity and specificity should have the highest priority.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15446574

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  4 in total

Review 1.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

2.  Circulating microRNAs as promising diagnostic biomarkers for pancreatic cancer: a systematic review.

Authors:  Jinru Xue; Erna Jia; Na Ren; Andrew Lindsay; Haixin Yu
Journal:  Onco Targets Ther       Date:  2019-08-19       Impact factor: 4.147

3.  Expression of novel tumor markers of pancreatic adenocarcinomas in intrahepatic cholangiocarcinomas.

Authors:  Meijuan Zong; Lei Jia; Liang Li
Journal:  Onco Targets Ther       Date:  2013-01-11       Impact factor: 4.147

Review 4.  Translational progress on tumor biomarkers.

Authors:  Hongwei Guo; Xiaolin Zhou; Yi Lu; Liye Xie; Qian Chen; Evan T Keller; Qian Liu; Qinghua Zhou; Jian Zhang
Journal:  Thorac Cancer       Date:  2015-07-27       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.